Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9421)
All Articles published online
|
Publishing Process of This Article
|
Oct 7, 2013 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2013; 19(37): 6144-6155 [PMID: 24115810 DOI: 10.3748/wjg.v19.i37.6144] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i37/6144.htm |
| Number | Citing Articles |
| 1 |
Soo Hyung Ryu, Myoung Kuk Jang, Woo Jean Kim, Danbi Lee, Young-Hwa Chung. Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine. Cancer and Metastasis Reviews 2014; 33(4): 965 doi: 10.1007/s10555-014-9522-4
|
| 2 |
Jiangfeng Hu, Chenlin Song, Bensong Duan, Xiaoyan Zhang, Dongliang Li, Liang Zhu, Hengjun Gao. LncRNA-SVUGP2 suppresses progression of hepatocellular carcinoma. Oncotarget 2017; 8(58): 97835 doi: 10.18632/oncotarget.18279
|
| 3 |
Paul R. Massey, Jonathan S. Okman, Julia Wilkerson, Edward W. Cowen. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature. Supportive Care in Cancer 2015; 23(6): 1827 doi: 10.1007/s00520-014-2520-9
|
| 4 |
Bénédicte Delire, Peter Stärkel. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. European Journal of Clinical Investigation 2015; 45(6): 609 doi: 10.1111/eci.12441
|
| 5 |
Junyu Huo, Jinzhen Cai, Liqun Wu. Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma. Cancer Medicine 2023; 12(1): 898 doi: 10.1002/cam4.4858
|
| 6 |
Bin Wei, Chunmei Guo, Shuqing Liu, Ming-Zhong Sun. Annexin A4 and cancer. Clinica Chimica Acta 2015; 447: 72 doi: 10.1016/j.cca.2015.05.016
|
| 7 |
Bing Jiang, Longfei Feng, Tao Yang, Wenjing Guo, Yangyang Li, Tao Wang, Chengguang Liu, Haixiang Su. Combination of chloroquine diphosphate and salidroside induces human liver cell apoptosis via regulation of mitochondrial dysfunction and autophagy. Molecular Medicine Reports 2022; 27(2) doi: 10.3892/mmr.2022.12924
|
| 8 |
Masayoshi Yamaguchi, Tomiyasu Murata, Joe W. Ramos. The calcium channel agonist Bay K 8644 promotes the growth of human liver cancer HepG2 cells in vitro: suppression with overexpressed regucalcin. Molecular and Cellular Biochemistry 2020; 472(1-2): 173 doi: 10.1007/s11010-020-03795-7
|
| 9 |
Ying Zheng, Xuemei Wang, Haidong Wang, Wei Yan, Quan Zhang, Xin Chang. Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway. Tumor Biology 2014; 35(6): 5189 doi: 10.1007/s13277-014-1673-y
|
| 10 |
Fengjie Xu, Runzhui Lin, Jianrui Liu, Zeming Chen, Hua Zhuo, Xingmu Liu, Dong-Hua Yang. Intravenous Immunoglobulin Inhibits Liver Cancer Progression by Promoting p38MAPK-Associated Apoptosis. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/1300989
|
| 11 |
Li-Hua Jiang, Ying-Li Hao, Jing-Wei Zhu. Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2019; 43(3): 282 doi: 10.1016/j.clinre.2018.09.011
|
| 12 |
YUWU LIU, CHANG WU, YING WANG, SAILAN WEN, JUNPU WANG, ZHIHONG CHEN, QIONGQIONG HE, DEYUN FENG. Loss of plexin-B3 in hepatocellular carcinoma. Experimental and Therapeutic Medicine 2015; 9(4): 1247 doi: 10.3892/etm.2015.2243
|
| 13 |
Prashant Sukharamwala, Daniel Hennessey, Thomas Wood, Shelly Singh, Carrie Ryan, Alexander Rosemurgy. Molecular profiles in foregut oncology. Cancer Genetics 2016; 209(12): 537 doi: 10.1016/j.cancergen.2016.09.008
|
| 14 |
Zhi-guang Fu, Li Wang, Hong-yong Cui, Jian-long Peng, Shi-jie Wang, Jie-jie Geng, Ji-de Liu, Fei Feng, Fei Song, Ling Li, Ping Zhu, Jian-li Jiang, Zhi-nan Chen. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells. Oncotarget 2016; 7(8): 9429 doi: 10.18632/oncotarget.6990
|
| 15 |
Hua Li, Qian Miao, Chun-wei Xu, Jian-hui Huang, Yue-fen Zhou, Mei-juan Wu. OTX1 Contributes to Hepatocellular Carcinoma Progression by Regulation of ERK/MAPK Pathway. Journal of Korean Medical Science 2016; 31(8): 1215 doi: 10.3346/jkms.2016.31.8.1215
|
| 16 |
Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang. Genetic alterations in hepatocellular carcinoma: An update. World Journal of Gastroenterology 2016; 22(41): 9069-9095 doi: 10.3748/wjg.v22.i41.9069
|
| 17 |
Huimin Shen, Hao Wu, Fengkai Sun, Jianni Qi, Qiang Zhu. A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma. Bioengineered 2021; 12(1): 240 doi: 10.1080/21655979.2020.1866303
|
| 18 |
Maria Daoudaki, Ioannis Fouzas. Hepatocellular carcinoma. Wiener Medizinische Wochenschrift 2014; 164(21-22): 450 doi: 10.1007/s10354-014-0296-7
|
| 19 |
Athina Kladi-Skandali, Kleita Michaelidou, Andreas Scorilas, Konstantinos Mavridis. Long Noncoding RNAs in Digestive System Malignancies: A Novel Class of Cancer Biomarkers and Therapeutic Targets?. Gastroenterology Research and Practice 2015; 2015: 1 doi: 10.1155/2015/319861
|
| 20 |
MINORU TOMIZAWA, FUMINOBU SHINOZAKI, YASUFUMI MOTOYOSHI, TAKAO SUGIYAMA, SHIGENORI YAMAMOTO, MAKOTO SUEISHI. Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells. Oncology Letters 2014; 8(5): 2023 doi: 10.3892/ol.2014.2484
|
| 21 |
Danbi Lee, Myoung-Kuk Jang, Ji Hae Seo, Soo Hyung Ryu, Jeong A. Kim, Young-Hwa Chung. ARD1/NAA10 in hepatocellular carcinoma: pathways and clinical implications. Experimental & Molecular Medicine 2018; 50(7): 1 doi: 10.1038/s12276-018-0106-1
|
| 22 |
Peng Lyu, Fengyue Li, Runzhi Deng, Qiliang Wei, Bingkai Lin, Lei Cheng, Bixing Zhao, Zhonglei Lu. Lnc-PIK3R1, transcriptionally suppressed by YY1, inhibits hepatocellular carcinoma progression via the Lnc-PIK3R1/miR-1286/GSK3β axis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2024; 1870(6): 167233 doi: 10.1016/j.bbadis.2024.167233
|
| 23 |
Gokhan Yildiz. Integrated multi‑omics data analysis identifying novel drug sensitivity‑associated molecular targets of hepatocellular carcinoma cells. Oncology Letters 2018; doi: 10.3892/ol.2018.8634
|
| 24 |
Lunxu Li, Shilin Xia, Xueying Shi, Xu Chen, Dong Shang. The novel immune-related genes predict the prognosis of patients with hepatocellular carcinoma. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-89747-7
|
| 25 |
Sana Ferroudj, Gokhan Yildiz, Mourad Bouras, Evin Iscan, Umut Ekin, Mehmet Ozturk. Role of Fanconi anemia/BRCA pathway genes in hepatocellular carcinoma chemoresistance. Hepatology Research 2016; 46(12): 1264 doi: 10.1111/hepr.12675
|
| 26 |
Yong-Ru Liu, Rui-Xue Tang, Wen-Ting Huang, Fang-Hui Ren, Rong-Quan He, Li-Hua Yang, Dian-Zhong Luo, Yi-Wu Dang, Gang Chen. Long noncoding RNAs in hepatocellular carcinoma: Novel insights into their mechanism. World Journal of Hepatology 2015; 7(28): 2781-2791 doi: 10.4254/wjh.v7.i28.2781
|
| 27 |
Gloria C. Bonel-Pérez, Amalia Pérez-Jiménez, Isabel Gris-Cárdenas, Alberto M. Parra-Pérez, José Antonio Lupiáñez, Fernando J. Reyes-Zurita, Eva Siles, René Csuk, Juan Peragón, Eva E. Rufino-Palomares. Antiproliferative and Pro-Apoptotic Effect of Uvaol in Human Hepatocarcinoma HepG2 Cells by Affecting G0/G1 Cell Cycle Arrest, ROS Production and AKT/PI3K Signaling Pathway. Molecules 2020; 25(18): 4254 doi: 10.3390/molecules25184254
|
| 28 |
Justin T. Huntington, Xing Tang, Lindsey N. Kent, Carl R. Schmidt, Gustavo Leone. The Spectrum of E2F in Liver Disease-Mediated Regulation in Biology and Cancer. Journal of Cellular Physiology 2016; 231(7): 1438 doi: 10.1002/jcp.25242
|
| 29 |
Jingwen Zhang, Ningning Wang, Xiaoxia Xie, Chunhong Yan, Fenghua Fu, Jianwen Yao, Hongbo Wang. Design, synthesis and biological activities of quinazoline containing sorafenib analogs as antitumor agents. Wuhan University Journal of Natural Sciences 2017; 22(3): 239 doi: 10.1007/s11859-017-1241-6
|
| 30 |
Chang Min Kim, Shin Hwang, Bhumsuk Keam, Yun Suk Yu, Ji Hoon Kim, Dong-Sik Kim, Si Hyun Bae, Gun-Do Kim, Jong Kyu Lee, Yong Bae Seo, Soon Woo Nam, Koo Jeong Kang, Luigi Buonaguro, Jin Young Park, Yun Soo Kim, Hee Jung Wang. Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. Liver Cancer 2020; 9(2): 182 doi: 10.1159/000504548
|
| 31 |
Zhi-Peng Sun, Jian Zhang, Li-Hong Shi, Xiu-Rong Zhang, Yu Duan, Wen-Fang Xu, Gong Dai, Xue-Jian Wang. Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition. Biomedicine & Pharmacotherapy 2015; 76: 65 doi: 10.1016/j.biopha.2015.10.023
|
| 32 |
Mirko Tarocchi, Simone Polvani, Giada Marroncini, Andrea Galli. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. World Journal of Gastroenterology 2014; 20(33): 11630-11640 doi: 10.3748/wjg.v20.i33.11630
|
| 33 |
Jian Zhang, Chunyan Fang, Meihua Qu, Huina Wu, Xuejuan Wang, Hongan Zhang, Hui Ma, Zhaolin Zhang, Yongxue Huang, Lihong Shi, Shujuan Liang, Zhiqin Gao, Weiguo Song, Xuejian Wang. CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy Agents. Frontiers in Pharmacology 2018; 9 doi: 10.3389/fphar.2018.01042
|
| 34 |
Priyadarshini Mohapatra, Natarajan Chandrasekaran. Wnt/β-catenin targeting in liver carcinoma through nanotechnology-based drug repurposing: A review. Biomedicine & Pharmacotherapy 2022; 155: 113713 doi: 10.1016/j.biopha.2022.113713
|
| 35 |
Xiao‐Lan Wang, Min Shi, Tian Xiang, Yan‐Zhi Bu. Long noncoding RNA DGCR5 represses hepatocellular carcinoma progression by inactivating Wnt signaling pathway. Journal of Cellular Biochemistry 2019; 120(1): 275 doi: 10.1002/jcb.27342
|
| 36 |
Thomas Couri, Anjana Pillai. Goals and targets for personalized therapy for HCC. Hepatology International 2019; 13(2): 125 doi: 10.1007/s12072-018-9919-1
|
| 37 |
Masayoshi Yamaguchi, Satoru Osuka, M. Neale Weitzmann, Bassel F. El-Rayes, Mamoru Shoji, Tomiyasu Murata. Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro. International Journal of Oncology 2016; 49(4): 1686 doi: 10.3892/ijo.2016.3669
|
| 38 |
Bingling Dai, Yujiao Ma, Tianfeng Yang, Mengying Fan, Runze Yu, Qi Su, Hongying Wang, Feng Liu, Changhua Yang, Yanmin Zhang. Synergistic effect of berberine and HMQ1611 impairs cell proliferation and migration by regulating Wnt signaling pathway in hepatocellular carcinoma. Phytotherapy Research 2019; 33(3): 745 doi: 10.1002/ptr.6267
|
| 39 |
Kai-Cai Liu, Wei-Fu Lv, Dong Lu, Yu-Lin Tan, Guo-Xiang Wang, Jia-Yin Dai, Xian-Hai Zhu, Bo Jiang, Shao-Bao Xu, Zong-Gen Gao, Chang-Sheng Shi, Ming-Xue Su. Comparing the Effectiveness and Safety of Sorafenib Plus TACE with Apatinib Plus Tace for Treating Patients with Unresectable Hepatocellular Carcinoma: A Multicentre Propensity Score Matching Study. SSRN Electronic Journal 2021; doi: 10.2139/ssrn.3959157
|
| 40 |
Qinggong Yuan, Yan Zhang, Junhui Li, Di Zhang, Wenbin Yang. Circ_TEX2 Functions as a Tumor Suppressor in Hepatoma via miR-96-5p/SPRED1 Axis. Molecular Biotechnology 2023; 65(10): 1679 doi: 10.1007/s12033-023-00669-3
|
| 41 |
Qianhui Chen, Xinyu Lu, Jiayi Xie, Na Ma, Weikang Xu, Zhiming Zhang, Xuan Huang, Hongyan Liu, Jinlin Hou, Xiaoyong Zhang, Wei Zhu. Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.813275
|
| 42 |
Dallyla Jennifer Morais de Sousa, Kynnara Gabriella Feitosa de Oliveira, Irislene Costa Pereira, Glauto Tuquarre Melo do Nascimento, Clenio Oliveira Barrense, Jorddam Almondes Martins, Beatriz de Mello Pereira Rêgo, Tiago Eugênio Oliveira da Silva, Felipe Cavalcanti Carneiro da Silva, Francisco Leonardo Torres-Leal. Dietary restriction and hepatic cancer: Systematic review and meta-analysis of animal studies. Critical Reviews in Oncology/Hematology 2024; 196: 104264 doi: 10.1016/j.critrevonc.2024.104264
|
| 43 |
LIMING CUI, BO GAO, ZHIGANG CAO, XIAOYING CHEN, SHIDE ZHANG, WEIZHE ZHANG. Downregulation of B7-H4 in the MHCC97-H hepatocellular carcinoma cell line by arsenic trioxide. Molecular Medicine Reports 2016; 13(3): 2032 doi: 10.3892/mmr.2016.4757
|
| 44 |
Masayoshi Yamaguchi. Involvement of regucalcin as a suppressor protein in human carcinogenesis: insight into the gene therapy. Journal of Cancer Research and Clinical Oncology 2015; 141(8): 1333 doi: 10.1007/s00432-014-1831-z
|
| 45 |
Gang Chen, Dongdong Wang, Xiongqi Zhao, Jun Cao, Yingpeng Zhao, Fan Wang, Jianhua Bai, Ding Luo, Li Li. miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling. Cancer Cell International 2017; 17(1) doi: 10.1186/s12935-017-0469-8
|
| 46 |
Helder Cardoso, Ana Margarida Alves, Margarida Marques, Ana Maria Vale, Pedro Pereira, Guilherme Macedo. Hepatocellular Carcinoma Treatment With Sorafenib: Real-Life Evaluation of Prognostic Factors and a Practical Clue for Patient Management. GE Portuguese Journal of Gastroenterology 2016; 23(5): 243 doi: 10.1016/j.jpge.2016.04.006
|
| 47 |
Bo Hu, Xiao-Bo Yang, Xin-Ting Sang. Molecular subtypes based on immune-related genes predict the prognosis for hepatocellular carcinoma patients. International Immunopharmacology 2021; 90: 107164 doi: 10.1016/j.intimp.2020.107164
|
| 48 |
Liang Yin, Kai-Cai Liu, Wei-Fu Lv, Dong Lu, Yu-Lin Tan, Guo-Xiang Wang, Jia-Ying Dai, Xian-Hai Zhu, Bo Jiang. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study. Cancer Imaging 2023; 23(1) doi: 10.1186/s40644-023-00574-7
|
| 49 |
Juhyun Kim, Ranhui Won, Guyee Ban, Mi Ha Ju, Kyung Sook Cho, Sang Young Han, Jin-Sook Jeong, Seong-Wook Lee. Targeted Regression of Hepatocellular Carcinoma by Cancer-Specific RNA Replacement through MicroRNA Regulation. Scientific Reports 2015; 5(1) doi: 10.1038/srep12315
|
| 50 |
Jun Fujita, Toshiharu Sakurai. Human Cell Transformation. Advances in Experimental Medicine and Biology 2019; 1164: 63 doi: 10.1007/978-3-030-22254-3_5
|
| 51 |
Surabhi Pathak, Mohamad Sonbol. Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. Journal of Hepatocellular Carcinoma 2021; : 1147 doi: 10.2147/JHC.S268314
|
| 52 |
Yong He, Xiao-Ming Meng, Cheng Huang, Bao-Ming Wu, Lei Zhang, Xiong-Wen Lv, Jun Li. Long noncoding RNAs: Novel insights into hepatocelluar carcinoma. Cancer Letters 2014; 344(1): 20 doi: 10.1016/j.canlet.2013.10.021
|
| 53 |
Jun Wang, Li Gong, Shao-Jun Zhu, Qiao Zhu, Li Yao, Xiu-Juan Han, Jia-Rui Zhang, Yan-Hong Li, Wei Zhang, Diego Calvisi. The Human Homolog of Drosophila Headcase Acts as a Tumor Suppressor through Its Blocking Effect on the Cell Cycle in Hepatocellular Carcinoma. PLOS ONE 2015; 10(9): e0137579 doi: 10.1371/journal.pone.0137579
|
| 54 |
Cholpajsorn Junhom, Natthida Weerapreeyakul, Waraporn Tanthanuch, Kanjana Thumanu. Partial least squares regression and fourier transform infrared (FTIR) microspectroscopy for prediction of resistance in hepatocellular carcinoma HepG2 cells. Experimental Cell Research 2017; 351(1): 82 doi: 10.1016/j.yexcr.2016.12.027
|
| 55 |
Sevil Uygun Ilikhan, Muammer Bilici, Hatice Sahin, Ayşe Semra Demir Akca, Murat Can, Ibrahim Ilker Oz, Berrak Guven, M Cagatay Buyukuysal, Yucel Ustundag. Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma. World Journal of Gastroenterology 2015; 21(22): 6999-7007 doi: 10.3748/wjg.v21.i22.6999
|
| 56 |
Parvin Zamani, Maryam Matbou Riahi, Amir Abbas Momtazi-Borojeni, Khadijeh Jamialahmadi. Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma. Artificial Cells, Nanomedicine, and Biotechnology 2018; 46(7): 1301 doi: 10.1080/21691401.2017.1388250
|
| 57 |
Youming Ding, Xiaoyan Chen, Bin Wang, Bin Yu, Jianhui Ge, Xiaokang Shi. Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of MEK1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells. Canadian Journal of Physiology and Pharmacology 2018; 96(5): 521 doi: 10.1139/cjpp-2017-0655
|
| 58 |
Priyadarshini Mohapatra, Natarajan Chandrasekaran, Amitava Mukherjee. Handbook of Research on Nanoemulsion Applications in Agriculture, Food, Health, and Biomedical Sciences. Advances in Chemical and Materials Engineering 2022; : 307 doi: 10.4018/978-1-7998-8378-4.ch014
|
| 59 |
Stacey Prenner, Laura Kulik. Zakim and Boyer's Hepatology. 2018; : 668 doi: 10.1016/B978-0-323-37591-7.00046-X
|
| 60 |
Qianping Zhou, Lanshan Huang, Yongyao Gu, Huiping Lu, Zhenbo Feng. The expression of CCL18 in diffuse large B cell lymphoma and its mechanism research. Cancer Biomarkers 2018; 21(4): 925 doi: 10.3233/CBM-171097
|
| 61 |
Masayoshi Yamaguchi, Tomiyasu Murata, Joe W. Ramos. The phytochemical p-hydroxycinnamic acid suppresses the growth and stimulates the death in human liver cancer HepG2 cells. Anti-Cancer Drugs 2021; 32(5): 558 doi: 10.1097/CAD.0000000000001059
|
| 62 |
Jianfeng Tian, Dengdi Hu. LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival. Clinics and Research in Hepatology and Gastroenterology 2021; 45(2): 101490 doi: 10.1016/j.clinre.2020.07.001
|